Brief: CytoDyn Receives FDA Guidance For Its HIV BLA Dose Justification Report
13/08/2021 11:24
Aug 13 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN RECEIVES FDA GUIDANCE FOR ITS HIV BLA DOSE
JUSTIFICATION
REPORT
* CYTODYN INC - CMC AND NON-CLINICAL SECTIONS WILL BE FULLY
RESUBMITTED AS EARLY AS SEPTEMBER 2021
* CYTODYN INC - BELIEVES ALL ISSUES ARE ADDRESSABLE AND IT
WILL
BE ABLE TO CONTINUE BLA RESUBMISSION FOR HIV
Source text for Eikon: ID:nGNX59g9RJ
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer